QualityStocks would like to highlight Access Pharmaceuticals, Inc. (OTCBB: ACCP), a biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. The company's products include MuGard™, which has received FDA marketing clearance for the management of patients with mucositis.
In the company’s news yesterday,
Access Pharmaceuticals said that Dr. Ron R. Allison of Carolina Radiation Medicine, Greenville, NC, recently presented results from the company’s ongoing MuGard phase 4 clinical trial in oral mucositis at the Multinational Association of Supportive Care in Cancer (MASCC) Conference in NYC, presenting summarized data from 70 cancer patients undergoing chemoradiation therapy for head and neck cancer.
Data shows that patients using MuGard experienced statistically significant efficacy in: reduction in mouth and throat pain, a common side effect of chemotherapies; a delay to onset of oral mucositis, a debilitating side effect of some radiation and chemotherapy cancer treatments; and reductions in weight loss during therapy and in the use of opioid pain medication.
“Given the significant oral mucositis typically seen in this head and neck cancer population, the benefits of MuGard shown in the results from this trial are important both clinically and from a patient quality-of-life perspective. It’s critically important that we keep patients as comfortable and nourished as possible during this tough treatment regimen, to optimize clinical outcomes,” Dr. Allison stated in the press release.
Jeffrey B. Davis, president and CEO of Access Pharmaceuticals, detailed two key values of MuGard, per current clinical trials.
“Access believes this MuGard data is ground breaking and unique from at least two perspectives. First, this is the first product that has ever shown a statistically significant positive clinical benefit in managing the pain symptoms and delaying the onset of oral mucositis in the very difficult to treat head and neck cancer population,” Davis stated. “Second, the rigorous design of the MuGard trial is the first of its kind in a medical device treatment option for oral mucositis, setting a new standard in this area. The clinical and quality-of-life benefits shown in this data echoes what we hear in the marketplace and that is evidenced in the increasing commercial adoption of MuGard.”
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
